Pembrolizumab induced steroid resistant immune mediated colitis and concurrent Clostridioides difficile infection

J Gastrointestin Liver Dis. 2021 Sep 22;30(3):411-413. doi: 10.15403/jgld-3923.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Clostridioides difficile / genetics
  • Clostridioides difficile / isolation & purification*
  • Clostridium Infections / diagnosis
  • Clostridium Infections / drug therapy
  • Colitis / chemically induced*
  • Colitis / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Polymerase Chain Reaction
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab